Ladenburg kept a Buy rating on UroGen Pharma (URGN) with a $31 price target following a transfer of coverage. The firm sees a “de-risked path” to approval for UGN-102.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
Questions or Comments about the article? Write to editor@tipranks.com